Amphstar Pharmaceuticals 对比 Corcept Therapeutics
可添加、更换或移除公司，最多四家。
简而言之
- Corcept Therapeutics 规模更大:2025 财年营收 $761M，Amphstar Pharmaceuticals 为 $720M。
- Corcept Therapeutics 营收增长更快(12.8%，对方为 −1.7%)。
- Amphstar Pharmaceuticals 每一美元销售额中留下的营业利润更多(营业利润率 19.5%，对方为 5.9%)。
- Corcept Therapeutics 将更多销售额转化为自由现金流(自由现金流利润率 18.6%，对方为 16.8%)。
- Corcept Therapeutics 的投入资本回报更高(15.7%，对方为 9.9%)。
| 最近财年 | AMPH · FY25 | CORT · FY25 |
|---|---|---|
| 规模 | ||
| 市值 | $1.1B | $10.2B |
| 营收 | $720M | $761M |
| 自由现金流 | $121M | $142M |
| 净利润 | $98.1M | $99.7M |
| 增长 | ||
| 营收增长 | −1.7% | 12.8% |
| 5年增长率 | 15.5% | 16.6% |
| 股数变化 | −7.4% | 5.7% |
| 盈利能力 | ||
| 毛利率 | 49.5% | 98.3% |
| 营业利润率 | 19.5% | 5.9% |
| 净利率 | 13.6% | 13.1% |
| 自由现金流利润率 | 16.8% | 18.6% |
| 资本回报率 | 9.9% | 15.7% |
| 股本回报率 | 12.9% | 15.0% |
| 资产负债表 | ||
| 净债务 | $339M | −$372M |
| 净债务 / EBITDA | 1.7x | −8.1x |
| 股息与回购 | $75.6M | $173M |
| 估值与质量 | ||
| 市盈率 | 14.9x | — |
| Piotroski F 分数 | 6 | 3 |
FY16
AMPH $255M
CORT $81.3M
FY17
AMPH $240M
CORT $159M
FY18
AMPH $295M
CORT $251M
FY19
AMPH $322M
CORT $307M
FY20
AMPH $350M
CORT $354M
FY21
AMPH $438M
CORT $366M
FY22
AMPH $499M
CORT $402M
FY23
AMPH $644M
CORT $482M
FY24
AMPH $732M
CORT $675M
FY25
AMPH $720M
CORT $761M
AMPH
CORT
FY16
AMPH 6.0%
CORT 12.5%
FY17
AMPH −0.5%
CORT 33.2%
FY18
AMPH −2.9%
CORT 35.6%
FY19
AMPH −0.0%
CORT 36.4%
FY20
AMPH 3.1%
CORT 36.2%
FY21
AMPH 16.0%
CORT 34.0%
FY22
AMPH 21.5%
CORT 28.0%
FY23
AMPH 30.6%
CORT 22.2%
FY24
AMPH 28.1%
CORT 20.3%
FY25
AMPH 19.5%
CORT 5.9%
AMPH
CORT
FY16
AMPH $17.2M
CORT $18.2M
FY17
AMPH $4.1M
CORT $60.5M
FY18
AMPH −$8.6M
CORT $115M
FY19
AMPH $0.2M
CORT $135M
FY20
AMPH $23.4M
CORT $151M
FY21
AMPH $70.5M
CORT $167M
FY22
AMPH $65.2M
CORT $120M
FY23
AMPH $145M
CORT $127M
FY24
AMPH $172M
CORT $196M
FY25
AMPH $121M
CORT $142M
AMPH
CORT
FY16
AMPH 3.7%
CORT —
FY17
AMPH −0.4%
CORT 99.0%
FY18
AMPH −2.1%
CORT 85.5%
FY19
AMPH −0.0%
CORT 109.6%
FY20
AMPH 1.4%
CORT 116.1%
FY21
AMPH 13.4%
CORT 95.4%
FY22
AMPH 20.9%
CORT 88.4%
FY23
AMPH 22.6%
CORT 87.6%
FY24
AMPH 16.4%
CORT 55.1%
FY25
AMPH 9.9%
CORT 15.7%
AMPH
CORT
各公司最近一个财年的数据；各公司财年结束月份不同。在越高(或越低)明显越好的行中，突出显示最佳值。不构成投资建议。